DOCSLIB.ORG

Best Evidence for Antithrombotic Agent Reversal in Bleeding

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

3/16/2021 1 JAMES H. PAXTON, MD • DIRECTOR OF CLINICAL RESEARCH • DETROIT RECEIVING HOSPITAL (DRH), DEPARTMENT OF EMERGENCY MEDICINE, WAYNE STATE UNIVERSITY • ATTENDING PHYSICIAN • SINAI-GRACE HOSPITAL (SGH) • DETROIT RECEIVING HOSPITAL (DRH) 2 1 3/16/2021 DISCLOSURES • FUNDED RESEARCH SPONSORED BY: TELEFLEX INC, 410 MEDICAL, HOSPI CORP. 3 OBJECTIVES •AT THE CONCLUSION OF THIS LECTURE, THE LEARNER WILL: • RECOGNIZE COMMON ANTITHROMBOTIC MEDICATIONS ASSOCIATED WITH BLEEDING EMERGENCIES • BE ABLE TO EXPLAIN THE MECHANISMS OF ACTION FOR COMMON ANTITHROMBOTIC MEDICATIONS • UNDERSTAND THE EVIDENCE FOR RAPID REVERSAL OF ANTITHROMBOTIC MEDICATIONS, INCLUDING CONTROVERSIES AND BEST PRACTICES HAVE FEWER NIGHTMARES ABOUT SCENES LIKE THE ONE ON THE NEXT SLIDE? 4 2 3/16/2021 BLEEDING IS BAD 5 WHEN TO REVERSE? • WHEN RISK OF BLEEDING OUTWEIGHS RISK OF REVERSAL: • INTRACRANIAL HEMORRHAGE (ICH) • OTHER CNS HEMATOMA (E.G., INTRAOCULAR, SPINAL) • EXSANGUINATING GASTROINTESTINAL (GI) BLEED • UNCONTROLLED RETROPERITONEAL BLEED • HEMORRHAGE INTO EXTREMITY WITH COMPARTMENT SYNDROME • CONSIDER IN POSTERIOR EPISTAXIS, HEMOTHORAX, PERICARDIAL TAMPONADE 6 3 3/16/2021 ANTITHROMBOTIC AGENTS •ANTI-PLATELET DRUGS •ANTI-COAGULANTS •FIBRINOLYTICS 7 THROMBOGENESIS • Primary component in arterial thrombosis (“white clot”) • Target for antiplatelet drugs • Primary component in venous thrombosis (“red clot”) • Aggregated platelets + • Target for anticoagulants fibrin mesh • Target for fibrinolytics 8 4 3/16/2021 PLATELET AGGREGATION Antiplatelet Drugs Mechanism Aspirin* Inhibit TXA2 synthesis Clopidogrel (Plavix)* Inhibit ADP receptor Prasugrel (Effient)* “-grel” activation Ticagrelor (Brillinta) Dipyridamole (Persantine) Lower Ca++ by elevating “-ol” Cilostazol (Pletal) cAMP Abciximab (ReoPro) Block GPIIb/IIIa receptors Tirofiban (Aggrestat) “-fib / -mab” Eptifibatide (Integrilin) * Permanent inhibition PLATELET LIFESPAN IS ∼8-10 DAYS! 9 REVERSAL OF ANTIPLATELET AGENTS • ACTIVATED CHARCOAL • IF INGESTION IS WITHIN 2-3 HRS (E.G., OVERDOSE), INTUBATED PATIENT • PLATELETS • THROMBOELASTOGRAPHY (TEG) MAY BE USEFUL – LIMITED EVIDENCE • DO NOT TRANSFUSE PLATELETS FOR ICH IF NO SURGICAL INTERVENTION IS PLANNED • CONSIDER 1 UNIT (6-10 PACKS) IF PFA-PLAVIX ASSAY IS POSITIVE (< 194 PRU) • DESMOPRESSIN (DDAVP) • CONSIDER SINGLE IV DOSE FOR INTRACRANIAL HEMORRHAGE • DOSE = 0.3-0.4 MCG/KG IV (NO MAX DOSE) • DECREASED LIKELIHOOD OF HEMATOMA EXPANSION IN FIRST 24 HRS (FELDMAN 2019) THERE IS NO EVIDENCE TO SUPPORT REVERSING ASPIRIN ALONE 10 5 3/16/2021 COAGULATION CASCADE 11 Oral Anticoagulants Warfarin (Coumadin) Inhibits SYNTHESIS of multiple factors ANTICOAGULANTS Dabigatran (Pradaxa) Inhibits ACTIVITY of Factor IIa Rivaroxaban (Xarelto) Inhibits ACTIVITY of Factor Xa Apixaban (Eliquis) Edoxaban (Savaysa) Betrixaban (Bevyxxa) Parenteral Anticoagulants Heparin Inhibits ACTIVITY of multiple factors LMWH: Inhibits ACTIVITY of Factors Xa & IIa Enoxaparin (Lovenox) Dalteparin (Fragmin) Fondaparinux (Arixtra) Inhibits ACTIVITY of Factor Xa Bivalirudin (Angiomax) Inhibits ACTIVITY of Factor IIa 12 6 3/16/2021 Factor Synonyms Source I Fibrinogen Liver CLOTTING II Prothrombin Liver (Vit K-dependent) III Tissue Factor, or Tissue Thromboplastin Liver FACTORS IV Calcium Liver V Labile Factor, or Proaccelerin Liver VI Accelerin Liver VII Stable Factor, or Proconvertin Liver (Vit K-dependent) VIII Antihemophilic Factor A Endothelium IX Christmas Factor, or Plasma Thromboplastin Liver (Vit K-dependent) Component (PTC), or Antihemophilic Factor B X Stuart-Prower Factor Liver (Vit K-dependent) XI Plasma Thromboplastin Antecedent (PTA) Liver XII Hageman Factor, or Glass Factor Liver XIII Fibrin Stabilizing Factor, or Laki-Lorand Factor Liver VITAMIN K-DEPENDENT FACTORS = “2 + 7 = 9, NOT 10” 13 • ACTS IN THE LIVER ONLY WARFARIN EFFECTS • COMPROMISES CARBOXYLATION, PREVENTING PRODUCTION OF GAMMA-CARBOXYGLUTAMIC ACID (GLA) RESIDUES • FACTORS THAT ENTER CIRCULATION WITH GLA RESIDUES ARE UNAFFECTED • PROTEIN C / S ALSO INHIBITED (8 HR / ??) Factor Synonyms Plasma Half-Life II Prothrombin 70 hours VII Stable Factor, or Proconvertin 3-6 hours IX Christmas Factor, or Plasma Thromboplastin 18-24 hours Component (PTC), or Antihemophilic Factor B X Stuart-Prower Factor 40 hours 14 7 3/16/2021 WARFARIN REVERSAL • LONG-ACTING DRUG • TERMINAL ½ LIFE AFTER SINGLE DOSE = 1 WEEK; EFFECTIVE ½ LIFE = 20-60 HOURS (MEAN ∼ 40 HOURS) • METABOLIZED IN THE LIVER (CYP2C9 ALLELE FOR P450 ENZYME) > KIDNEY; DRUG-DRUG INTERACTIONS • TREATMENT • WITHHOLD DRUG, CONSERVATIVE MANAGEMENT, SUPPORTIVE THERAPIES • RESERVE REPLETION OF VIT K-DEPENDENT FACTORS FOR LIFE-THREATENING EVENTS (E.G., EXSANGUINATION, ICH) • RISK FROM BASELINE PROTHROMBOTIC STATE, OR “OVERSHOOT” THROMBOEMBOLIC COMPLICATIONS WITH REPLETION 15 WARFARIN REVERSAL • VITAMIN K • GRADUAL EFFECT OVER HOURS TO DAYS – INEFFECTIVE FOR LIFE-THREATENING BLEEDS (AS MONOTHERAPY) • NECESSARY TO GIVE IF GIVING FFP OR PCC, TO AVOID REBOUND INR ELEVATIONS • DOSE = 10 MG (FOR LIFE-THREATENING BLEED); “CONSIDER 5-10 MG” IF HEMODYNAMICALLY STABLE • IV GIVEN OVER > 20 MIN TO AVOID ANAPHYLACTOID REACTION; ONSET = 1-2 HRS, PEAK = 4-6 HRS • ANAPHYLACTOID REACTION (NON-IGE-MEDIATED) • THOUGHT TO BE DUE TO POLYETHOXYLATED CASTOR OIL DILUENT (NO LONGER USED) (MI 2014) • SEEN IN <0.03% OF CASES (RIEGERT-JOHNSON 2002) • DO NOT GIVE SQ / IM • CONSIDER RE-DOSING (10 MG IV) FOR ICH IF INR > 1.4 AFTER 24-48 HRS (FRONTERA 2016) 16 8 3/16/2021 WARFARIN REVERSAL • FRESH FROZEN PLASMA (FFP) • INCLUDES ALL FACTORS, PROTEIN C, VWF • DOSE = 10-15 ML/KG; 1 UNIT = 200-250 ML • LIMITED BY TIME THAWING, CROSS-MATCHING, CONCERNS OF VOLUME OVERLOAD, POOR EFFICACY, TRALI, TACO • INTRINSIC INR = 1.5 (NO PROVEN BENEFIT FOR INR < 1.7) • NOT RECOMMENDED FOR REVERSAL A/W INTRACRANIAL HEMORRHAGE (FRONTERA 2016) • RECOMBINANT FACTOR VIIA (NOVOSEVEN®) • 100 U/KG @ $1.94/U = $15,000 / DOSE • MORE PRO-THROMBOTIC IN VITRO THAN PCC; UNCOMMONLY USED FOR WARFARIN REVERSAL • LOW-DOSE (1000-1200 MCG) MORE EFFECTIVE THAN 3FPCC (20 IU/KG) IN REDUCING INR (CHAPMAN 2014) 17 WARFARIN REVERSAL • PROTHROMBIN COMPLEX CONCENTRATE (PCC) • POOLED, VIRUS-INACTIVATED CONCENTRATES OF HUMAN CLOTTING FACTORS • SUPERIOR TO FFP IN WARFARIN-ASSOCIATED INTRACRANIAL HEMORRHAGE (STEINER 2016) • MORE THROMBOEMBOLIC COMPLICATIONS (5-10%, DOSE-DEPENDENT) THAN FFP (DENTALI 2011, MILLING 2016) • THREE-FACTOR PCC (3FPCC) = FACTORS II, IX, X (AND VERY LOW LEVELS OF VII) • PROFILNINE ® / BEBULIN ® • CAN BE COMBINED WITH RECOMBINANT FACTOR VIIA – LIMITED DATA ON EFFICACY 18 9 3/16/2021 WARFARIN REVERSAL • FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE (4FPCC) = ADDS FACTOR VII, PROTEIN C/S • COST = $1.65 / IU = $6,600 FOR 50 IU/KG @ 80 KG • KCENTRA® • BEST EVIDENCE SUPPORTS FIXED DOSING (1,000-1,500 IU; MORE FOR OBESE, ICH, INR>4) (RHONEY 2020) • LEXI-COMP: 25 IU/KG (INR 2 TO <4), 35 IU/KG (INR 4-6), 50 IU/KG (INR >6) • INR CORRECTION FASTER THAN 3PCC, W/SIMILAR MORTALITY, LOS, THROMBOSES, BLOOD USE (HOLT 2018; DEANGELO 2018) • 3.6-8% THROMBOSIS RATES @ 30 DAYS (MAJEED 2017, SCHULMAN 2018) VS. 7.8% FFP (SARODE 2013) • FACTOR EIGHT INHIBITOR BYPASSING ACTIVITY (FEIBA®) = ACTIVATED PCC (APCC) • USED FOR HEMOPHILIA FOR DECADES; DOSE = 50-100 U/KG Q 6-12 HRS UNTIL RESOLUTION • HAS ACTIVATED FACTOR VII, AND NO HEPARIN (UNLIKE KCENTRA®) FACTOR VII = SHORT ½ LIFE, INITIATES EXTR. PATHWAY = MORE PROTHROMBOTIC 19 SOURCE: FRONTERA 2016 20 10 3/16/2021 REBOUND AFTER WARFARIN REVERSAL IF INR > 1.4 AFTER 24-48 HRS FOLLOWING PCC, CONSIDER FFP / RE-DOSING VIT K 21 DIRECT ORAL ANTICOAGULANTS (DOACS) Drug Factor Inhibited Cmax (Hrs) Half-Life (Hrs) Reversal Agents Dabigatran (Pradaxa) Factor IIa 2 12-17 Idarucizumab (Praxbind), PCC Rivaroxaban (Xarelto) 2-4 5-9 Apixaban (Eliquis) 1-3 12 Factor Xa Andexanet Alfa (Andexxa), PCC Edoxaban (Savaysa) 1-2 10-14 Betrixaban (Bevyxxa) 3-4 19-27 22 11 3/16/2021 DABIGATRAN (PRADAXA) REVERSAL • IDARUCIZUMAB (PRAXBIND) • HUMANIZED MONOCLONAL ANTIBODY FRAGMENT (BINDS DABIGATRAN) • 350X HIGHER AFFINITY TO DABIGATRAN THAN THROMBIN • ONLY FDA-APPROVED REVERSAL AGENT FOR DABIGATRAN • RE-VERSE AD TRIAL (POLLACK 2015) • ONSET IN MINUTES, CLINICAL HEMOSTASIS ∼ 11.4 HRS • 6.3% THROMBOEMBOLIC EVENTS @ 90 DAYS (90% IN PTS NOT RE-INITIATED ON ANTICOAGULATION) • DOSE = 5 GM IV, ADMINISTERED IN TWO 2.5 GM DOSES • COST = $3,600 / 5-GM DOSE • PCC MAY BE USED (MARLU 2012, SCHULMAN 2017), BUT LIMITED EVIDENCE OF EFFICACY 23 FACTOR XA INHIBITOR REVERSAL • ANDEXANET ALFA (ANDEXXA) • RECOMBINANT, MODIFIED FACTOR XA MOLECULE (“FACTOR XA DECOY”) – FDA APPROVED 2018 • HIGH AFFINITY FOR ALL FACTOR XA INHIBITORS • DOSING • EDOXABAN / BETRIXABAN = 800 MG IV BOLUS @ 30 ML/MIN, THEN 8 MG/MIN FOR UP TO 120 MIN (HIGH DOSE) • APIXABAN / RIVAROXABAN = 400 MG IV BOLUS @ 30 ML/MIN, THEN 4 MG/MIN FOR UP TO 120 MIN (LOW DOSE) OR HIGH DOSE (DEPENDS ON AMOUNT AND TIMING OF LAST DOSE) • COST = $22,000 / DOSE • 10% THROMBOTIC RATE, 82% ACHIEVED GOOD CONTROL OF HEMORRHAGE (CONNOLLY 2019) 24 12 3/16/2021 FACTOR XA INHIBITOR REVERSAL • ANDEXANET ALFA (ANDEXXA) • ONLY REVERSES INHIBITION EFFECT DURING THE ACTUAL 2-HOUR INFUSION (REBOUND @ 4 HRS) • THEORY = ALLOWS A HEMOSTATIC PLUG TO FORM BEFORE REBOUND • ANNEXA-4 TRIAL (CONNOLLY 2019) • HETEROGENEOUS POPULATION, 352 PTS (64% ICH, 26% GIB), WITHIN 18 HRS OF LAST DOSE • MOSTLY APIXABAN (55%) > RIVAROXABAN (36%) > ENOXAPARIN (6%), EDOXABAN (3%) • 92% REDUCTION IN ANTI-FACTOR XA ACTIVITY W/ DOACS; 75% REDUCTION W/ENOXAPARIN • LACK OF CONTROL GROUP • ONLY 58% OF PATIENTS IN THE UPDATE WERE ELIGIBLE FOR EFFICACY ANALYSIS
Recommended publications
  • 201370Orig1s000

    201370Orig1s000

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 201370Orig1s000 MEDICAL REVIEW(S) M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH Date: July 8, 2011 From: Kathy M. Robie-Suh, M.D., Ph.D. Medical Team Leader Division of Hematology Products Subject: NDA 201370, resubmission April 11, 2011 Heparin Sodium Injection (heparin sodium, USP) Sponsor: Pfizer, Inc. 235 East 42nd Street New York, NY 10017-5755 To: NDA 201370 This is the second review cycle for this 505(b)(2) application for a new Heparin Sodium Injection product derived from porcine intestine. The presentations include several containing benzyl alcohol as a preservative and one preservative-free presentation. The first cycle review of the NDA found the application acceptable from a clinical viewpoint. However, manufacturing facilities inspection identified deficiencies that precluded approval and a Complete Response (CR) letter was issued on April 7, 2011. Labeling review was not completed at that time. In the current resubmission the sponsor has responded to the identified deficiencies deleting the two heparin supplier sites where deficiencies were found. The Amended Cross-Discipline Team Leader Review by Dr. Ali Al-Hakim (6/28/2011) comments that Office of Compliance has updated its recommendation in the Establishment Evaluation System and issued “ACCEPTABLE” overall recommendation for this NDA on June 27, 2011 and therefore the NDA is recommended for approval. No new clinical information is included in the resubmission. Clinical review of the original application and the resubmission was conducted by Dr.
  • Spontaneous Epidural Hematoma of the Cervical Spine Following Thrombolysis in a Patient with STEMI—Two Medical Specialties Facing a Rare Dilemma

    Spontaneous Epidural Hematoma of the Cervical Spine Following Thrombolysis in a Patient with STEMI—Two Medical Specialties Facing a Rare Dilemma

    Published online: 2019-12-05 THIEME Case Report 191 Spontaneous Epidural Hematoma of the Cervical Spine Following Thrombolysis in a Patient with STEMI—Two Medical Specialties Facing a Rare Dilemma Anastasios Tsarouchas1 Dimitrios Mouselimis1 Constantinos Bakogiannis1 Grigorios Gkasdaris2 George Dimitriadis3 Dimitrios Zioutas4 Christodoulos E. Papadopoulos1 13rd Cardiology Department, Hippokrateio University Hospital, Address for correspondence Grigorios Gkasdaris, MD, Department Aristotle University of Thessaloniki, Thessaloniki, Greece of Neurosurgery, KAT General Hospital of Attica, Athens 145 61, 2Department of Neurosurgery, KAT General Hospital of Attica, Greece (e-mail: [email protected]). Athens, Greece 3General Hospital of Katerini, Katerini, Greece 4St. Luke’s Hospital, Thessaloniki, Greece J Neurosci Rural Pract 2020;11:191–195 Abstract Spontaneous spinal epidural hematoma (SSEH) is a rare, albeit well-documented complication following thrombolysis treatment in ST elevation myocardial infarction (STEMI). A SSEH usually manifests with cervical pain and neurologic deficits and may require surgical intervention. In this case report, we present the first reported SSEH to occur following thrombolysis with reteplase. In this case, the SSEH manifested with cervical pain shortly after the patient emerged from his rescue percutaneous coronary intervention (PCI). Although magnetic resonance imaging reported spinal cord com- Keywords pression, the lack of neurologic symptoms prompted the treating clinicians to delay ► spinal epidural surgery. A dangerous dilemma emerged, as the usual antithrombotic regimen that hematoma was necessary to avoid stent thrombosis post-PCI, was also likely to exacerbate the ► spontaneous spinal bleeding. As a compromise, the patient only received aspirin as a single antiplatelet epidural hematoma therapy. Ultimately, the patient responded well to conservative treatment, with the ► cervical spine hematoma stabilizing a week later, without residual neurologic deficits.
  • Full Prescribing Information for - Active Internal Bleeding (4) RETAVASE

    Full Prescribing Information for - Active Internal Bleeding (4) RETAVASE

    HIGHLIGHTS OF PRESCRIBING INFORMATION CONTRAINDICATIONS These highlights do not include all the information needed to use • Do not use in patients with: RETAVASE safely and effectively. See full prescribing information for - Active internal bleeding (4) RETAVASE. - Recent stroke (4) - Recent intracranial or intraspinal surgery or serious head trauma (4) RETAVASE (reteplase) for injection, for intravenous use - Intracranial neoplasm, arteriovenous malformation, or aneurysm (4) Initial U.S. Approval: 1996 - Known bleeding diathesis (4) - Severe uncontrolled hypertension (4) INDICATIONS AND USAGE RETAVASE is a tissue plasminogen activator (tPA) indicated for treatment of WARNINGS AND PRECAUTIONS acute ST-elevation myocardial infarction (STEMI) to reduce the risk of death • Increases the risk of bleeding. Avoid intramuscular injections. (5.1) and heart failure. (1) • Hypersensitivity (5.2) • Cholesterol embolism (5.3) Limitation of Use: The risk of stroke may outweigh the benefit produced by thrombolytic therapy in patients whose STEMI puts them at low risk for death ADVERSE REACTIONS or heart failure. (1) The most common adverse reaction (>5%) is bleeding. (6.1) DOSAGE AND ADMINISTRATION To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA, • Two 10 unit intravenous injections, each administered over 2 minutes, Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or 30 minutes apart. (2.1) www.fda.gov/medwatch. • No other medication should be injected or infused simultaneously via the same intravenous line or added to the injection solution. (2.1) USE IN SPECIFIC POPULATIONS • Pediatric Use: Safety and effectiveness have not been established. (8.4) DOSAGE FORMS AND STRENGTHS For Injection: 10 units as a lyophilized powder in single-use vials for Revised: 10/2020 reconstitution co-packaged with Sterile Water for Injection, USP in 10 mL prefilled syringe.
  • Dosing and Administration Guide for RETAVASE® (Reteplase) for Injection1

    Dosing and Administration Guide for RETAVASE® (Reteplase) for Injection1

    RETAVASE® (reteplase) is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin degrades the fibrin matrix of the thrombus, exerting its thrombolytic action. Dosing and administration guide for RETAVASE® (reteplase) for injection1 RETAVASE is a tissue plasminogen activator (tPA) with the convenience of fixed dosing for your fibrinolytic needs in acute STEMI Administration with zero dose calculations As soon as possible after the 30 minutes later, administer onset of STEMI, administer 10 units 30min a second dose of 10 units intravenously over 2 minutes. intravenously. Each single-use vial contains 10 units of RETAVASE as lyophilized powder. Reconstitute RETAVASE immediately before administration using only the co-packaged Sterile Water for Injection, USP (see instructions on back). Indication and Usage Important Safety Information RETAVASE is a tissue plasminogen activator (tPA) Heparin and RETAVASE are incompatible. Do not administer indicated for treatment of acute ST-elevation RETAVASE through an intravenous line containing heparin. myocardial infarction (STEMI) to reduce the risk of death and heart failure. The most common adverse reaction (>5%) is bleeding. Limitation of Use: The risk of stroke may outweigh Please see Full Important Safety the benefit produced by thrombolytic therapy in Information on back. patients whose STEMI puts them at low risk for death or heart failure. Reconstitution instructions for RETAVASE® (reteplase) — the only fixed-dose fibrinolytic for acute STEMI1 Indication and Usage STEP 1 STEP 2 RETAVASE is a tissue plasminogen activator (tPA) indicated Uncap Clean vial for treatment of acute ST-elevation myocardial infarction spike, vial membrane (STEMI) to reduce the risk of death and heart failure.
  • Pharmacoepidemiological.Study.Protocol.. ER1379468. A.Retrospective.Cohort.Study.To.Investigate.The.Initiation. And.Persistence.Of.Dual.Antiplatelet.Treatment.After

    Pharmacoepidemiological.Study.Protocol.. ER1379468. A.Retrospective.Cohort.Study.To.Investigate.The.Initiation. And.Persistence.Of.Dual.Antiplatelet.Treatment.After

    Pharmacoepidemiological.study.protocol.ER1379468. % . % % % % % Pharmacoepidemiological.study.protocol.. ER1379468. A.retrospective.cohort.study.to.investigate.the.initiation. and.persistence.of.dual.antiplatelet.treatment.after.. acute.coronary.syndrome.in.a.Finnish.setting.–.THALIA. % Author:(( ( ( Tuire%Prami( Protocol(number:(( %% ER1359468,%ME5CV51306( Sponsor:(( ( ( AstraZeneca%Nordic%Baltic% Protocol(version:(( ( 2.0( Protocol(date:(( ( ( 03%Jul%2014% ( . EPID%Research%Oy%. CONFIDENTIAL. % Pharmacoepidemiological.study.protocol.ER1379468... Version.2.0. 03.Jul.2014. Study Information Title% A% retrospective% cohort% study% to% investigate% the% initiation% and% persistence% of% dual% antiplatelet%treatment%after%acute%coronary%syndrome%in%a%Finnish%setting%–%THALIA% Protocol%version% ER1359468% identifier% ME5CV51306% EU%PAS%register% ENCEPP/SDPP/6161% number% Active%substance% ticagrelor%(ATC%B01AC24),%clopidogrel%(B01AC04),%prasugrel%(B01AC22)% Medicinal%product% Brilique,% Plavix,% Clopidogrel% accord,% Clopidogrel% actavis,% Clopidogrel% krka,% Clopidogrel% mylan,%Clopidogrel%orion,%Clopidogrel%teva%pharma,%Cloriocard,%Efient% Product%reference% N/A% Procedure%number% N/A% Marketing% AstraZeneca%Nordic%Baltic:%Brilique%(ticagrelor)% authorization% holder% financing%the%study% Joint%PASS% No% Research%question% To%describe%initiation%and%persistence%of%dual%antiplatelet%treatment%in%invasively%or%non5 and%objectives% invasively%treated%patients%hospitalized%for%acute%coronary%syndrome%% Country%of%study% Finland% Author% Tuire%Prami%
  • In Vivo Effects of Contrast Media on Coronary Thrombolysis

    In Vivo Effects of Contrast Media on Coronary Thrombolysis

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector 1102 JACC Vol. 32, No. 4 October 1998:1102–8 In Vivo Effects of Contrast Media on Coronary Thrombolysis SORIN PISLARU, MD, PHD,*† CRISTINA PISLARU, MD,* MONIKA SZILARD, MD,* JEF ARNOUT, PHD,‡ FRANS VAN DE WERF, MD, PHD, FACC* Leuven, Belgium and Bucharest, Romania Objectives. The aim of the present study was to evaluate the associated with longer reperfusion delays (time to optimal reper- influence of radiographic contrast media (CM) on alteplase- fusion: 67 6 48 min and 65 6 49 min, respectively, vs. 21 6 11 min induced coronary thrombolysis. after placebo; p < 0.05) and shorter periods of coronary perfusion Background. Contrast media inhibit fibrinolysis in vitro and (optimal perfusion time: 21 6 26 min and 21 6 28 min, respec- interact with endothelial cells, platelets and the coagulation tively, vs. 58 6 40 min after placebo; p < 0.05). No significant system. The in vivo effects of CM on thrombolysis are not known. differences were observed between groups with regard to activated Methods. Occlusive coronary artery thrombosis was induced in partial thromboplastin times, circulating thrombin-antithrombin 4 groups of 10 dogs by the copper coil technique. After 70 min of III complex concentrations and fibrinogen. occlusion the dogs were randomized to intracoronary injection of Conclusions. In this animal model administration of iohexol 2 2mlkg 1 of either saline, a low-osmolar ionic CM (ioxaglate), a and amidotrizoate before thrombolysis significantly delayed low-osmolar nonionic CM (iohexol) or a high-osmolar ionic CM reperfusion.
  • Use of Antithrombotic Medications in the Presence of Neuraxial Anesthesia

    Use of Antithrombotic Medications in the Presence of Neuraxial Anesthesia

    Guideline: Use of Antithrombotic Medications In The Presence of Neuraxial Anesthesia Use of Antithrombotic Medications In The Presence of Neuraxial Anesthesia Purpose of Guidelines: To establish appropriate administration and timing of antithrombotic medications before, during, and after the use of neuraxial anesthesia to minimize the risk of bleeding. Definitions: Neuraxial Anesthesia = Delivery of anesthetic medication requiring placement of catheters or needles into the epidural or spinal space Antithrombotic Medications = Anticoagulant, antiplatelet, and thrombolytic medications Background1-3: Spinal (or epidural) hematomas are a rare but catastrophic complication of neuraxial anesthesia. The risk of hematoma development is increased in the presence of antithrombotic medication. Patients undergoing neuraxial anesthesia must have the risks of bleeding from neuraxial interventions balanced with the underlying and ongoing risk of thromboembolism necessitating anticoagulation. Recommendations for the management of specific antithrombotics in patients undergoing neuraxial anesthesia are provided in the following Tables: o Table 1. Management of Intravenous and Subcutaneous Anticoagulation Therapy in Patients Undergoing Neuraxial Anesthesia o Table 2. Management of ORAL Anticoagulation Therapy in Patients Undergoing Neuraxial Anesthesia o Table 3. Management of ORAL and Intravenous Antiplatelet and Thrombolytic Therapy in Patients Undergoing Neuraxial Anesthesia Workflow if a Contradicted Medication is Prescribed: Providers will have
  • List Item Refludan : EPAR

    List Item Refludan : EPAR

    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures which have been finalised before 1 August 2003. For scientific information on procedures after this date please refer to module 8B. I Introduction Refludan contains Lepirudin ([Leu1-Thr2]-63-desulfohirudin) as the active substance. Lepirudin is a hirudin analogue produced in yeast cells transfected with an expression vector containing the hirudin gene. Refludan is presented as a powder to be reconstituted with water for injection or with isotonic saline for intravenous injection or infusion. It is supplied in one strength with a standardised content of 50 mg lepirudin per vial. The specific activity of lepirudin is approximately 16,000 (Antithrombin Units) ATU per mg, where one ATU is the amount of hirudin that neutralises one unit of the WHO preparation of thrombin (89/588). Lepirudin is a specific direct inhibitor of free and clot-bound thrombin and the proposed therapeutic indication is anticoagulation in adult patients with heparin-associated thrombocytopenia (HAT) type II and thromboembolic disease mandating parenteral antithrombotic therapy. HAT type II is a complication of heparin therapy, with a probable incidence of the order of 1% of heparin-treated patients. The disorder is characterised by, sometimes profouauthorisednd, thrombocytopenia and a high propensity for venous and arterial thromboembolic complications occurring during continued heparin treatment. Mortality and amputation rates of 20-30% and 10-20%, respectively, are cited in the more recent literature reviews. The chief underlying pathogenic mechanism seems to be a formation of antibodies directed mainly against a complex of heparin and Platelet Factor 4.
  • Update in Standard of Care for Venous Thromboembolism from the June 2012 Supplement to CHEST and 2017 AC Forum

    Update in Standard of Care for Venous Thromboembolism from the June 2012 Supplement to CHEST and 2017 AC Forum

    Update in Standard of Care for Venous Thromboembolism from the June 2012 supplement to CHEST and 2017 AC Forum Sharyl Magnuson, MD Adjunct Faculty, Pacific University School for PA Studies former Associate Medical Director, Lovelace Clinical Thrombosis Center Member THSNA Disclosures • Nothing to disclose from pharmaceutical sources of income. • I have been an Investigator on many Pharmaceutical sponsored Clinical trials, last more than 7 years ago. • I have been a promotional speaker in the past for Xarelto, last more than 2 years ago. Scope of the Problem • “On average, one American dies of a blood clot every 6 minutes” 100,000/year. National Blood Clot Alliance • The precise number of people affected by DVT/PE is unknown, although as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the United States. • Estimates suggest that 60,000-100,000 Americans die of DVT/PE (also called venous thromboembolism). • 10 to 30% of people will die within one month of Clot diagnosis. • Sudden death is the first symptom in about one-quarter (25%) of people who have a PE. • Among people who have had a DVT, one-half will have long-term complications (post-thrombotic syndrome) such as swelling, pain, discoloration, and scaling in the affected limb. • One-third (about 33%) of people with DVT/PE will have a recurrence within 10 years. • Cdc.gov Best Resource • MAQI2 version 1.7, the Michigan Anticoagulation Quality Improvement Initiative, a consortium of AC clinics and experts across MI, produced this 65pg Quick Reference using updated review literature.
  • Melagatran Und Ecarinzeit.Pdf

    Melagatran Und Ecarinzeit.Pdf

    Wednesday , August 06, 2003 1 Effects of Lepirudin, Argatroban and Melagatran and Additional Influence of Phenprocoumon on Ecarin Clotting Time Tivadar Fenyvesi* M.D., Ingrid Jörg* M.D., Christel Weiss + Ph.D., Job Harenberg* M.D. Key words: direct thrombin inhibitors, ecarin clotti ng time, oral anticoagulants, enhancing effects *IV. Department of Medicine +Institute for Biometrics and Medical Statistics University Hospital Mannheim Theodor Kutzer Ufer 1 - 3 68167 Mannheim Germany *Corresponding author Phone: +49 -621 -383 -3378 E-ma il: tivadar.fenyvesi @med1.ma.uni -heidelberg.de Version 06.08.03 for Thromb Res Review Copy Elsevier 1 of 22 Wednesday , August 06, 2003 2 Abstract Introduction: Direct thrombin inhibitors (DTI) prolong the ecarin clotting time (ECT). Oral anticoagulants (OA) decrease prothrombin levels and thus interacts with actions of DTIs on the ECT method during concomitant therapy. Materials and methods: Actions of lepirudin, argatroban, and melagatran on ECT were investigated in normal plasma (NP) and in plasma of patients (n = 23 each) on stable therapy with phenprocoumon (OACP). Individual line characteristics were tested statistically. Results: Control ECT in OACP was prolonged compared to NP (50.1±0.9 vs. 45.7±0.8 sec; p < 0.001). Lepirudin prolonged the ECT linearly. Argatroban and melagatran delivered biphasic dose-response curves. OA showed additive effects on the ECT of lepirudin but not of argatroban and melagatran. Both in NP and OACP the first and second slopes of melagatran were steeper compared to argatroban (primary analysis; p<0.001). When using the same drug, slopes in OACP were steeper than in NP (secondary analysis; p<0.001).
  • Refludan, INN-Lepirudin

    Refludan, INN-Lepirudin

    ANNEXE I autorisé RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUIT plus n'est médicament Ce 1 1. DENOMINATION DU MEDICAMENT Refludan, 20 mg, poudre pour solution injectable ou pour perfusion 2. COMPOSITION QUALITATIVE ET QUANTITATIVE Chaque flacon contient 20 mg de lépirudine. (La lépirudine est un produit ADN recombinant dérivé de cellules de levure) Pour une liste complète des excipients, voir rubrique 6.1. 3. FORME PHARMACEUTIQUE Poudre pour solution injectable ou pour perfusion. Poudre lyophilisée blanche à presque blanche. 4. DONNEES CLINIQUES 4.1 Indications thérapeutiques autorisé Inhibition de la coagulation chez des patients adultes atteints d'une thrombopénie induite par l'héparine (TIH) de type II et de maladie thrombo-embolique nécessitant un traitement antithrombotique par voie parentérale. plus Le diagnostic devrait être confirmé par le test d'activation plaquettaire induite par l'héparine (HIPAA = Heparin Induced Platelet Activation Assay) ou un test équivalent. n'est 4.2 Posologie et mode d’administration Le traitement par Refludan devrait être débuté sous le contrôle d'un médecin ayant une expérience des troubles de l’hémostase. Posologie initiale Inhibition de la coagulation chezmédicament des patients adultes atteints d'une TIH de type II et de maladie thrombo-embolique : Ce 0,4 mg/kg de poids corporel en bolus intraveineux, suivi de 0,15 mg/kg de poids corporel/heure en perfusion intraveineuse continue pendant 2 à 10 jours, voire plus si l'état clinique du patient le nécessite. La posologie dépend du poids corporel du patient jusqu'à 110 kg. Chez les patients pesant plus de 110 kg, la posologie ne doit pas dépasser celle calculée pour les patients pesant 110 kg (voir aussi tableaux 2 et 3 ci-après).
  • Neuroradiology Fine Needle Spinal Procedures and Anticoagulation: Fine Needle Spinal Procedure: 20 Gauge Needle Or Smaller

    Neuroradiology Fine Needle Spinal Procedures and Anticoagulation: Fine Needle Spinal Procedure: 20 Gauge Needle Or Smaller

    Neuroradiology Fine Needle Spinal Procedures and Anticoagulation: Fine needle spinal procedure: 20 gauge needle or smaller. Typically 20 or 22 gauge is used. Medication Recommendation Aspirin & NSAIDS -Does NOT need to be stopped. Warfarin -Stop 5 days prior. -Check INR: INR ≤ 1.2 is normal. Proceed. *INR of 1.3 or 1.4 requires 24 hrs of post procedure monitoring. INR of ≥1.5LP not done. Thrombolytics (tPA) Unsafe. Should not be used pre or post procedure. Time frame uncertain. Heparin SQ (DVT prophylaxis) -Check platelets if on heparin ≥5 days. 5000 units SQ BID -No contraindication or delay if standard dosing of 5000 units SQ BID. -If given ≥ TID or > 5,000 units/dose or > 10,000 units /day: follow heparin IV protocol. Heparin IV -Wait 2-4 hours after last dose of IV heparin. -Document normal PTT. -Check platelets if on heparin ≥5 days. -Wait at least 1 hr after procedure to restart heparin drip. LMWH (Enoxaparin) prophylaxis -Wait 12 hrs after last dose to perform procedure. 30 mg SQ BID or -Wait 24 hrs after LP to restart med. 40 mg SQ daily LMHW (Enoxaparin) treatment -Wait 24 hrs after last dose to perform procedure. 1-1.5 mg/kg/day -Wait 24 hrs to restart med. Fondaparinux (Arixtra) -Withhold based on Cr. Cr Cl >50 wait 2-3 days; Cr Cl < 50 wait 3-5 days Clopidogrel (Plavix) Stop 5 days prior. Ticlopidine (Ticlid) Stop 14 days prior. Abciximab (ReoPro) (IIb/IIIa) Stop 2 days prior. Eptifibatide (Integrilin) (IIb/IIIa) Stop 4-8 HOURS prior. Tirofiban (Aggrastat) (IIb/IIIa) Stop 8 HOURS prior.